pfizer glp 1 agonist Phase IIb Data Support Monthly GLP-1 Dosing for Obesity China Opens Its Weight-Loss Drug

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging

While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5 to 15.8 []

This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.

Includes PREDIMED data and EU health claim context.

Plasma concentrations of semaglutide were determined using a validated liquid chromatography-tandem mass spectrometry (LCMS/MS) method

Thousands of people trust it for accurate results